We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · January 24, 2023

ICI and Targeted Therapy for Melanoma

Journal of the European Academy of Dermatology and Venereology: JEADV


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of the European Academy of Dermatology and Venereology: JEADV
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study
J Eur Acad Dermatol Venereol 2022 Nov 25;[EPub Ahead of Print], A Thiem, P Mashhadiakbar, C Cussigh, JC Hassel, I Grimmelmann, R Gutzmer, M Schlaak, MV Heppt, P Dücker, S Hüning, L Schulmeyer, B Schilling, S Haferkamp, M Ziemer, RKC Moritz, V Hagelstein, P Terheyden, C Posch, MR Gaiser, P Kropp, S Emmert, B Müller, JK Tietze

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading